期刊
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
卷 464, 期 4, 页码 1260-1266出版社
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.bbrc.2015.07.116
关键词
Astragaloside IV; Renal fibroblasts; Proliferation; Transdifferentiation; ECM production; Transforming growth factor-beta (TGF-beta)
资金
- Shanghai Science and Technology Committee [13401906100, 12401906400, 14140903200]
- National Basic Research Program of China 973 Program [2012CB517602]
- National Key Technology RD Program [2011BAI10B08]
- National Natural Science Foundation of China [81373865]
- Program of Shanghai Health Bureau [ZYSNXD012-RC-ZXY017]
- Shanghai Municipal Education Committee [ZZjdyx3049]
Renal fibrosis, a progressive process characterized by the accumulation of extracellular matrix (ECM) leading to organ dysfunction, is a characteristic of chronic kidney diseases. Among fibrogenic factors known to regulate the renal fibrotic process, transforming growth factor-beta (TGF-beta) plays a central role. In the present study, we examined the effect of Astragaloside IV (AS-IV), a component of the traditional Chinese medicinal plant Astragalus membranaceus, on the processes associated with renal fibrosis in cultured mouse renal fibroblasts treated with TGF-beta 1. RT-PCR, western blotting, immunofluorescence staining and collagen assays showed that AS-IV suppressed TGF-beta 1 induced fibroblast proliferation, transdifferentiation, and ECM production in a dose-dependent manner. Examination of the underlying mechanisms showed that the effect of AS-IV on the inhibition of fibroblast differentiation and ECM formation were mediated by its modulation of the activity of the MAPK and NF-kappa B signaling pathways. Taken together, our results indicate that AS-IV alleviates renal interstitial fibrosis via a mechanism involving the MAPK and NF-kappa B signaling pathways and demonstrate the therapeutic potential of AS-IV for the treatment of chronic kidney diseases. (C) 2015 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据